[{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"a896ec8e-9825-4531-a478-c93b653bba25","acronym":"","url":"https://clinicaltrials.gov/study/NCT02057133","created_at":"2021-01-17T17:28:58.622Z","updated_at":"2025-02-25T14:00:24.405Z","phase":"Phase 1","brief_title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","source_id_and_acronym":"NCT02057133","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CDK4 • CDK6","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"c1553d6e-ee80-4192-a7ab-63e94535e0af","acronym":"PRIMED","url":"https://clinicaltrials.gov/study/NCT05520723","created_at":"2022-08-30T20:55:50.589Z","updated_at":"2024-07-02T16:35:03.596Z","phase":"Phase 2","brief_title":"Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED","source_id_and_acronym":"NCT05520723 - PRIMED","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 12/14/2025","primary_completion_date":" 12/14/2025","study_txt":" Completion: 12/14/2025","study_completion_date":" 12/14/2025","last_update_posted":"2024-05-15"},{"id":"7e75ac94-fd8b-42e6-8ac2-7780bc50078b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04038619","created_at":"2024-04-05T15:40:34.993Z","updated_at":"2024-07-02T16:35:05.277Z","phase":"Phase 1","brief_title":"Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients","source_id_and_acronym":"NCT04038619","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL6 • CD4","pipe":"","alterations":" ","tags":["IL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e loperamide"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-08"},{"id":"afc27ea6-6597-4dab-94b4-678d114ae2f5","acronym":"nextMONARCH 1","url":"https://clinicaltrials.gov/study/NCT02747004","created_at":"2021-01-17T17:26:29.019Z","updated_at":"2024-07-02T16:35:09.614Z","phase":"Phase 2","brief_title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT02747004 - nextMONARCH 1","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 09/14/2016","start_date":" 09/14/2016","primary_txt":" Primary completion: 06/15/2018","primary_completion_date":" 06/15/2018","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-16"},{"id":"db496152-074a-4f24-8709-efd837f605cb","acronym":"ASPRIA","url":"https://clinicaltrials.gov/study/NCT04434040","created_at":"2021-01-18T21:21:04.269Z","updated_at":"2024-07-02T16:35:22.544Z","phase":"Phase 2","brief_title":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","source_id_and_acronym":"NCT04434040 - ASPRIA","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-01-23"},{"id":"327d0ed8-e8d1-4d0f-9ef7-67bdf45498bd","acronym":"DIANER","url":"https://clinicaltrials.gov/study/NCT05252988","created_at":"2022-02-23T19:55:12.531Z","updated_at":"2024-07-02T16:35:26.111Z","phase":"Phase 2","brief_title":"Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib","source_id_and_acronym":"NCT05252988 - DIANER","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • loperamide"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 03/25/2025","primary_completion_date":" 03/25/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-12-15"},{"id":"fedc9e7d-89aa-4cee-acd2-a8ecd4f1e103","acronym":"","url":"https://clinicaltrials.gov/study/NCT03094052","created_at":"2021-01-18T15:14:38.972Z","updated_at":"2024-07-02T16:35:28.996Z","phase":"Phase 2","brief_title":"Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib","source_id_and_acronym":"NCT03094052","lead_sponsor":"University of California, San Francisco","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • Mytesi (crofelemer) • loperamide"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 10/09/2018","start_date":" 10/09/2018","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-11-16"},{"id":"56c40cbf-abec-4a8e-9c55-5f5a9dd7863c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04366713","created_at":"2021-01-18T21:06:13.433Z","updated_at":"2024-07-02T16:35:55.861Z","phase":"Phase 2","brief_title":"A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib","source_id_and_acronym":"NCT04366713","lead_sponsor":"Puma Biotechnology, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • capecitabine • loperamide"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 12/28/2021","primary_completion_date":" 12/28/2021","study_txt":" Completion: 12/28/2021","study_completion_date":" 12/28/2021","last_update_posted":"2023-02-10"},{"id":"b05fff92-f69a-41af-8c68-038b45933e8d","acronym":"CONTROL","url":"https://clinicaltrials.gov/study/NCT02400476","created_at":"2021-01-18T11:27:13.156Z","updated_at":"2024-07-02T16:36:10.837Z","phase":"Phase 2","brief_title":"An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide","source_id_and_acronym":"NCT02400476 - CONTROL","lead_sponsor":"Puma Biotechnology, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • loperamide"],"overall_status":"Completed","enrollment":" Enrollment 563","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 04/22/2021","primary_completion_date":" 04/22/2021","study_txt":" Completion: 04/22/2021","study_completion_date":" 04/22/2021","last_update_posted":"2022-05-06"},{"id":"548f3079-15af-4e8f-8aed-13029a221cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05154396","created_at":"2021-12-13T14:12:33.186Z","updated_at":"2024-07-02T16:36:19.580Z","phase":"Phase 2","brief_title":"Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer","source_id_and_acronym":"NCT05154396","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • loperamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2021-12-13"},{"id":"fcc799e4-4858-48cc-938f-7d17cf4c2458","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576208","created_at":"2021-01-18T21:50:46.943Z","updated_at":"2024-07-02T16:36:37.262Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788","source_id_and_acronym":"NCT04576208","lead_sponsor":"Takeda","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib) • loperamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 07/31/2022","study_completion_date":" 07/31/2022","last_update_posted":"2020-12-17"},{"id":"a7f9b195-c17c-4dc6-8661-dd447843d3b4","acronym":"neoMONARCH","url":"https://clinicaltrials.gov/study/NCT02441946","created_at":"2021-01-18T11:41:59.031Z","updated_at":"2024-07-02T16:36:44.102Z","phase":"Phase 2","brief_title":"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT02441946 - neoMONARCH","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • loperamide"],"overall_status":"Completed","enrollment":" Enrollment 224","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 08/16/2016","primary_completion_date":" 08/16/2016","study_txt":" Completion: 02/12/2018","study_completion_date":" 02/12/2018","last_update_posted":"2020-06-17"},{"id":"26104115-4f98-45ad-93a8-51dfd4dab4c8","acronym":"PRECISO","url":"https://clinicaltrials.gov/study/NCT01633203","created_at":"2021-01-18T07:01:06.397Z","updated_at":"2024-07-02T16:36:45.663Z","phase":"","brief_title":"Observational Study of Perioperative Chemotherapy in Gastric Cancer","source_id_and_acronym":"NCT01633203 - PRECISO","lead_sponsor":"Grupo Oncologico Cooperativo Chileno de Investigation","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • capecitabine • epirubicin • dexamethasone injection • granisetron intravenous • loperamide • ondansetron intravenous"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-04-24"},{"id":"0f95261c-7a16-4a8a-ae55-c8f22dd7d760","acronym":"ELATE","url":"https://clinicaltrials.gov/study/NCT01205217","created_at":"2021-01-18T04:49:50.579Z","updated_at":"2024-07-02T16:37:21.305Z","phase":"Phase 2","brief_title":"Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer","source_id_and_acronym":"NCT01205217 - ELATE","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • cyclophosphamide • epirubicin • cyclophosphamide intravenous • loperamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2017-06-07"}]